A new vector system known as lentiviral vectors can permanently integrate the gene into dividing and non-dividing cells. The capacity of lentiviral vectors to reliably integrate at various genomic ...

Cell and gene therapies rely on engineered viruses to deliver them to their cellular destinations. While the progress of these types of medicines is evident in a growing number of FDA product ...

Lentiviral vectors are important gene delivery tools for cell and gene therapies, notably chimeric antigen receptor T-cell (CAR-T cell) therapies which have proven successful in treating a growing ...

Acquired from the human immunodeficiency virus (HIV), lentiviral vectors are one of the most practical and commonly used viral vectors. They provide the ability to transduce both non-dividing and ...

Lentiviral vectors have emerged as indispensable tools in gene therapy, offering the ability to integrate therapeutic genes into both dividing and non-dividing cells. Their unique capacity to achieve ...

Vector BioMed raised $15 million in a first round of funding as the startup looks to help fill a big gap in the manufacture of cell and gene therapies. The latest entry into the CDMO viral vector ...

Viral vectors are critical components of cell and gene therapy products, and they require extensive characterization to ensure their safe and effective use. Capillary electrophoresis is a proven ...

As a lab within the Cooperative Center of Excellence in Hematology (CCEH) at Fred Hutch, the Vector Production core assists investigators with the design, construction, and/or production of viral ...

Lentiviral vectors are increasingly popular as gene delivery tools for cell and gene therapies. Their value has been demonstrated within CAR-T and TCR therapies for blood malignancies that don’t ...

GERMANTOWN, Md. and PRAGUE, Czech Republic, May 18, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ORGS) (“Orgenesis”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT ...

In one of the largest private rounds raised by an Italian biotech, Genespire Srl has closed a €46.6 million (US$51.88 million) series B, enabling it to lay the ground for a phase I/II clinical trial ...